

## Ubiquitin Affinity Control Beads

Cat. # CUB02-Beads

Lot:

Upon arrival, store at 4°C (desiccated)

See datasheet for storage after reconstitution

<b>Form:</b>	Lyophilized powder
<b>Amount of material:</b>	1 x 220 µl when reconstituted
<b>Validated applications:</b>	IP
<b>Species reactivity:</b>	All

### Background Information

Ubiquitin (Ub) and ubiquitin-like proteins (Ubls, e.g. SUMO, Nedd) are a group of approximately 15 proteins that have a molecular weight of around 8 kD. During the ubiquitination process, these are conjugated via activating (E1), conjugating (E2) and ligating (E3) enzymes to lysines of a target protein (1). Mammalian cells express over 600 potential ubiquitin ligases which exceeds that of the kinase superfamily of PTM proteins (2).

One function of ubiquitination is to target proteins for proteosomal degradation. This role can range from a general housekeeping function that clears miss-folded proteins from a cell to involvement in tightly regulated spatio-temporal cell signaling events (1). An emerging function of ubiquitination is its ability to activate proteins via the creation of unique protein:protein interactions (3). In common with many other PTMs, ubiquitination is reversible. Ubiquitin-specific proteases (USPs or DUBs) remove ubiquitins from target proteins (4). The reversible nature of ubiquitination further enhances the potential of this PTM to dynamically regulate protein function.

When a protein of interest (POI) is ubiquitinated the percentage of modified protein is very low i.e. usually <1% of the POI. This low level of modified protein is sufficient to mediate profound regulatory changes at the cellular level but it presents the technical challenge of detection. To detect the low level of modified protein requires some form of enrichment. Cytoskeleton's ubiquitin affinity beads are a powerful tool for the complete analysis of a POI ubiquitin profile (see Figure 1). When performing ubiquitinated protein enrichment it is important to include a control bead that is as similar to the enrichment beads as possible but lacks the ability to bind ubiquitinated proteins. The CUB02-beads contain point mutations in the ubiquitin affinity binding domains of the ubiquitin enrichment beads (UBA01-beads) and offer an excellent control bead for enrichment IPs.

### Material

Ubiquitin affinity control beads contain crosslinked mutated Ubiquitin Binding Domains (UBDs/TUBES). The control beads are a powerful control for the complete analysis of a protein ubiquitin profile and allow the assessment of non-specific binding.

### Storage and Reconstitution

Shipped at ambient temperature. The lyophilized CUB02-Beads can be stored desiccated at 4°C for 6 months. For reconstitution, the product tube should be briefly centrifuged to collect the lyophilized beads at the bottom of the tube. Reconstitute each tube in 220µl of Milli-Q water to achieve 50% slurry and store at 4°C. Allow the beads to rehydrate completely before use (2-5 minutes). Final buffer composition is 50 mM Tris pH 8.0, 5 mM EDTA, 5% sucrose, and 1% dextran. When stored and reconstituted as described, the product is stable for at least 6 months in 4°C.

### Applications


**Control bead to assess non-specific binding in immunoprecipitation (IP) Applications**

Use 20 µl bead slurry for IP. Sufficient for 10 ubiquitin IP control reactions. See Figure 1 for representative data.

#### Application 1: Detection of Endogenously Ubiquitinated Rac1

The data shown in figure 1 agrees with published transfection data and demonstrates the utility of UBA01-Beads in studying the rapidly growing area of small G-protein regulation by ubiquitination (5-8). Control beads allow determination of specific Ub-Rac1 signal (Fig. 1 lane 2).

Figure 1: Detection of Endogenous Ubiquitinated Rac1



Swiss 3T3 cells were either untreated (Lane 3) or treated (Lane 4) with bacterial toxin CNF1 for 3 hours prior to lysis in BLASTR™ buffer. Lysates (300 µg per assay) were treated as outlined in the Signal-Seeker™ Ubiquitin Enrichment manual, each reaction used 40 µl of beads. The western blot was probed with an anti-Rac1 antibody. CNF1 treatment resulted in detection of mono- and polyubiquitinated species of Rac1 which agrees with previous reports (5). Lane 1, 3% of input signal; Lane 2, control beads (CUB02-Beads) plus lysate. The protease inhibitor MG132 was included in all lysates (10 µM/3h). Clear ubiquitin signals were also detected in the absence of MG132 (data not shown).

### IP and WB Method:

1. Flick tube containing Ubiquitin Affinity Bead 1 suspension several times to make sure that the beads are completely resuspended in the tube.
2. For each IP assay, aliquot 20 µl of bead suspension into a tube on ice.
2. Flick tube containing Ubiquitin IP Control Bead suspension several times to make sure that the beads are completely resuspended in the tube.
3. Aliquot 20 µl of bead suspension for a control reaction to determine non-specific binding of ubiquitinated species.
4. Add lysate. We recommend 0.5-1.0 mg of lysate per assay as a starting point. NOTE: the amount of lysate required will vary depending upon the abundance of modified target protein. We also recommend that the IP reaction be carried out in a 50% RIPA buffer.
5. Save a small amount of lysate (20 µl) to run as a western input lysate control.
6. Incubate the tubes on a rotating platform at 4°C for 2h.
7. Collect beads by centrifugation at 3-5,000 x g for 1 minute at 4°C.
8. Aspirate off as much supernatant as possible without disturbing the beads.
9. Wash beads in Wash buffer such as 50% RIPA buffer for 5 minutes on a 4°C rotating platform.
10. Collect beads by centrifugation at 3-5,000 x g for 1 minute at 4°C.
11. Aspirate off as much supernatant as possible without disturbing the beads.
12. Repeat the wash step two more times.
13. After the final wash, completely remove buffer supernatant without disturbing the bead pellet. Optional Technical Tip: remove residual supernatant using a fine bore protein loading tip.

14. Resuspend the beads in 30  $\mu$ l of **2x non-reducing** SDS sample buffer (125mM Tris pH6.8, 20% glycerol, 4% SDS, 0.005% Bromophenol blue).
15. Mix the beads by gently tapping the end of the tube, we do not recommend using a pipette for this. Incubate the solution at room temperature for 5 min. Collect supernatant by centrifuge tube at maximum speed for 1 min at 4°C.
16. Add 1  $\mu$ l of beta mercaptoethanol to a new Eppendorf tube. Carefully remove sample from step 6 without disturbing the beads and transfer to the new tube containing beta mercaptoethanol. Boil sample for 5 min prior to loading on SDS-PAGE.
17. Run protein sample in SDS-PAGE and perform western blot analysis on the POI.

#### Product Citations/Related Products

For the latest citations and related products please visit [www.cytoskeleton.com](http://www.cytoskeleton.com)

#### References

- 1) Grabbe, C. et al. 2011. The spatial and temporal organization of ubiquitin networks. *Nat. Rev. Mol. Cell. Biol.* 12:295-307.
- 2) Deshaies R.J. & Joazeiro, C.A. 2009. RING domain E3 ligases. *Ann. Rev. Biochem.* 78: 399-434.
- 3) Lomeli, H. & Vazquez. 2011. Emerging roles of the SUMO pathway. *Cell Mol. Life Sci.* 68:4045-4064.
- 4) Faesen, A.C. et al. 2012. The role of UBL domains in ubiquitin specific proteases. *Biochem. Soc. Trans.* 40:539-545.
- 5) Torino S. et al. 2011. The E3 ubiquitin-ligase HACE1 catalyses the ubiquitination of active RAc1. *Developmental Cell* 21: 959-965.
- 6) Nethe P. & Hordijk P. 2010. The role of ubiquitylation and degradation in RhoG-TPase signaling. *J. Cell Sci.* 123: 4011-4018.
- 7) Ding F. et al. 2011. Ubiquitination in Rho signaling. *Curr. Topics Med. Chem.* 11: 2879-2887.
- 8) Visvikis O. et al. 2010. Direct modifications of Rho proteins: deconstructing GTPase regulation. *Biol. Cell* 102: 377-389.
- 9) Jin L. et al. 2013. Epigallocatechin gallate promotes p53 accumulation and activity via the inhibition of MDM2-mediated p53 ubiquitination in human lung cancer cells. *Onc. Rep.* 29: 1983-1990.

#### Limited Use Statement

The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of product and components of product in research conducted by the buyer. The buyer cannot sell or otherwise transfer this product or any component thereof to a third party or otherwise use this product or its components for commercial purposes. Commercial purposes include, but are not limited to: use of the product or its components in manufacturing; use of the product or its components to provide a service; resale of the product or its components.

The terms of this Limited Use Statement apply to all buyers including academic and for-profit entities. If the purchaser is not willing to accept the conditions of this Limited Use Statement, Cytoskeleton Inc. is willing to accept return of the unused product with a full refund.

Some of the technology used in this product has been licensed under Patent US 8,716,441 B2.